Summit Therapeutics is trading 10.25% up now at $14.73 after partner Akeso reported positive topline HARMONi-GI1 results on August 26, 2026.
- Phase III achieved statistically significant overall-survival superiority versus durvalumab plus chemotherapy, meeting progression-free-survival and objective-response-rate endpoints in 682 patients.
- August 25's positive global HARMONi results in The Lancet Oncology reinforced investor enthusiasm.
- Biotech-sector strength provides support (XBI up 2.06%); direct catalyst is company-specific trial news; no volume data was provided to assess activity.